CorNeat EverPatch Synthetic Tissue Substitute Now Available in the US

CorNeat Vision announced the commerical launch of the CorNeat EverPatch, a synthetic tissue-integrating matrix for ocular surface surgeries.

The EverPatch, which received FDA 510(k) clearance in June 2023, offers a combination of features that provide an advantage over existing tissue grafts, which degrade over time, according to CorNeat. Its novel structure enables seamless integration with surrounding tissue without triggering a chronic foreign body response, and its non-degradability permanently reinforces the ocular surface. The CorNeat EverPatch provides a solution for reinforcing tissue over glaucoma drainage devices, addressing complications such as tube exposure that often require reoperation. At only 100 microns thick, the device is significantly thinner than tissue grafts, allowing it to conform better to the eye wall.

"Our synthetic tissue substitute is tear-resistant, non-degradable, and completely bio-compatible, with no observed chronic inflammatory response that exists around tissue grafts," Dr. Gilad Litvin, Co-Founder and Chief Medical Officer at CorNeat Vision, said in a company news release. "We are tracking over one hundred devices that we supplied to 25 US ophthalmic centers in the past couple of months, with excellent feedback. We are confident that the CorNeat EverPatch will set a new standard of care in ocular surgeries necessitating scleral reinforcement."

Now commercially available in the United States and select countries, CorNeat Vision will showcase the CorNeat EverPatch at the upcoming American Glaucoma Society (AGS) and American Society of Cataract and Refractive Surgery (ASCRS) annual meetings.